Expand The Potential For Medicine

Posted on by

Expand the potential for medicine with Brent Zettl, President & Chief Executive Officer of ZYUS. Zettl, BSA Distinction (Agriculture), is the leading pioneer of the Canadian medical cannabis industry and has led many of Canada’s significant advancements in patient care and cannabis clinical research. He founded Prairie Plant Systems Inc. in 1988 which eventually became the sole provider of legal medical cannabis products to Health Canada through the years 2000 to 2013. In 2017, PPS combined with CanniMed Therapeutics to list on TSX. In March 2018, CanniMed was acquired by Aurora Cannabis Inc. for CAD$1.1-billion. Advancements in biopharmaceuticals are dramatically improving health outcomes and transforming our expectations of disease. Despite successful treatment, however, people continue to suffer from pain and discomfort due to chronic disease, treatment side effects or conditions related to aging. ZYUS was founded by Brent Zettl and his industry-leading senior management team from the medicinal cannabis sector, who have a collective clear purpose to expand the potential for medicine by advancing the science of well-being. The ZYUS Vision: To forge a new industry of phytotherapeutics and elevate its solutions as a standard of care for treating disease and managing the experience of it. ZYUS is upgrading a global-scale ethanol extraction facility that will source dry herbal feedstock cannabis material from multiple Canadian licensed cannabis producers (LPs), thereby taking advantage of a dry herbal capacity overbuild widely anticipated to emerge within the next one to two years. ZYUS is solely focused on the development of pharmaceutical-grade medicinal oil products and dedicated to improving patient well-being, which is highly unique and well placed relative to the overall direction of the domestic and global industry. The timing for ZYUS’s business plan is particularly attractive due to a number of industry trends and indicators. Cannabis oil and oil derivative products are poised to become the majority of the domestic and global cannabis markets. These markets are anticipated to grow rapidly over the next ten years. These value-added oil products require a high level of expertise to successfully establish commercial extraction facilities and produce pharmaceutical-grade cannabinoid formulations on the scale.